Gross Profit for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current gross profit (TTM) is $3.03B USD. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingGross ProfitSwitch metric
TTM (last 4 quarters)
$3.03B
YoY change
+57.8%
5Y CAGR
+48.9%
Peak year (2025)
$3.04B
Cumulative gross profit
$9.53B
Gross Profit history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Gross Profit history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Gross Profit | YoY |
|---|---|---|---|---|
| 2025 | $3.04B | +57.8% | ||
| 2024 | $1.92B | +26.8% | ||
| 2023 | $1.52B | +74.8% | ||
| 2022 | $868.60M | +23.4% | ||
| 2021 | $704.14M | +69.8% | ||
| 2020 | $414.80M | +113.1% | ||
| 2019 | $194.69M | +166.3% | ||
| 2018 | $73.11M | -4.5% | ||
| 2017 | $76.55M | +62.3% | ||
| 2016 | $47.16M | +14.8% | ||
| 2015 | $41.10M | -18.7% | ||
| 2014 | $50.56M | +7.2% | ||
| 2013 | $47.17M | -29.3% | ||
| 2012 | $66.72M | -19.4% | ||
| 2011 | $82.76M | -17.3% | ||
| 2010 | $100.04M | -0.5% | ||
| 2009 | $100.53M | +4.5% | ||
| 2008 | $96.16M | +88.9% | ||
| 2007 | $50.90M | +89.0% | ||
| 2006 | $26.93M | +371.1% | ||
| 2005 | $5.72M | +33.6% | ||
| 2004 | $4.28M | +2330.7% | ||
| 2003 | $176,000 | — | ||
| 2002 | $0 | — |
Gross Profit values are taken from Alnylam Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Alnylam Pharmaceuticals (ALNY) most recent annual gross profit stands at $3.04B (2025) – surged 57.8% year-over-year.
Alnylam Pharmaceuticals gross profit compound annual growth for the 2020–2025 (5 years) window is +48.9%, sustaining 7 straight years of year-over-year growth.
Across the available history, gross profit reached its high of $3.04B in 2025 and its low of $0 in 2002.
Within Healthcare, Alnylam Pharmaceuticals (ALNY) ranks 9th among 8 peers we track. The peer median for gross profit is $53.80B.
Alnylam Pharmaceuticals Gross Profit by Year
Alnylam Pharmaceuticals Gross Profit 2025: $3.04B
Alnylam Pharmaceuticals gross profit in 2025 was $3.04B, surged 57.8% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Gross Profit 2024: $1.92B
Alnylam Pharmaceuticals gross profit in 2024 was $1.92B, grew 26.8% from 2023.
Alnylam Pharmaceuticals Gross Profit 2023: $1.52B
Alnylam Pharmaceuticals gross profit in 2023 was $1.52B, surged 74.8% from 2022.
Alnylam Pharmaceuticals Gross Profit 2022: $868.60M
Alnylam Pharmaceuticals gross profit in 2022 was $868.60M, grew 23.4% from 2021.
Alnylam Pharmaceuticals Gross Profit 2021: $704.14M
Alnylam Pharmaceuticals gross profit in 2021 was $704.14M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Gross Profit
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest gross profit.
| Company | Gross Profit | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $250.28B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $82.92B | Healthcare |
| Johnson & Johnson (JNJ) | $68.56B | Healthcare |
| Eli Lilly and Company (LLY) | $54.62B | Healthcare |
| Merck & Co., Inc. (MRK) | $52.98B | Healthcare |
| AstraZeneca PLC (AZN) | $48.11B | Healthcare |
| AbbVie Inc. (ABBV) | $42.96B | Healthcare |
| Amgen Inc. (AMGN) | $26.01B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's gross profit?
- Latest reported gross profit for Alnylam Pharmaceuticals (ALNY) is $3.03B (period ending December 31, 2025).
How has Alnylam Pharmaceuticals gross profit changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) gross profit changed +57.8% year-over-year on the latest annual filing.
What is the long-term growth rate of Alnylam Pharmaceuticals gross profit?
- Alnylam Pharmaceuticals (ALNY) gross profit compound annual growth rate is +48.9% over the most recent 5 years available.
When did Alnylam Pharmaceuticals gross profit hit its highest annual value?
- Alnylam Pharmaceuticals gross profit reached its highest annual value of $3.04B in 2025.
What was Alnylam Pharmaceuticals gross profit in 2024?
- Alnylam Pharmaceuticals (ALNY) gross profit in 2024 was $1.92B.
What was Alnylam Pharmaceuticals gross profit in 2025?
- Alnylam Pharmaceuticals (ALNY) gross profit in 2025 was $3.04B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.